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Classic strategies for peripheral blood progenitor cell (PBPC)
mobilization include daily administration of a growth factor, such
as ﬁlgrastim, alone or with marrow suppressive chemotherapy. A
single injection of pegﬁlgrastim has been shown to be comparable
to daily injections of ﬁlgrastim in the treatment of chemotherapy-
induced neutropenia. One of the objectives of this phase 1–2 study
was to provide dose-ﬁnding information regarding the efﬁcacy and
kinetics of cytokine-alone PBPC mobilization with pegﬁlgrastim.
Methods: Chemotherapy-naive subjects with a variety of solid
tumors were randomized to receive a single administration of 6, 12,
or 18 mg of pegﬁlgrastim on day 1 or daily administration of 10
g/kg ﬁlgrastim from day 1 until day 7. Daily blood samples for
peripheral CD34 analysis were collected on days 1–7 and then on
days 9 and 12. No chemotherapy was administered during this
cycle. For each subject, peak CD34 cell count was deﬁned as the
maximum cell count observed between days 3 to 7, inclusive.
Results: Of 61 subjects randomized into the study, all received
study drug (15 subjects each in the pegﬁlgrastim 12 mg and 18 mg
and ﬁlgrastim groups and 16 subjects in the pegﬁlgrastim 6 mg
group). The treatment groups were balanced in terms of demo-
graphics and baseline characteristics. The most common tumor
types were non-small cell lung cancer (n  23 [38%]) and ovarian
(n  19 [31%]). The mean peak CD34 cell count was similar in
the ﬁlgrastim and pegﬁlgrastim 6mg groups (4.51 and 4.24 
104/ml, respectively), whereas the pegﬁlgrastim 12 mg and 18 mg
groups had higher mean peaks (8.18 and 9.96  104/ml, respec-
tively). Pegﬁlgrastim 12 mg and 18 mg mobilized signiﬁcantly
more peripheral CD34 cells than ﬁlgrastim (P  .034 and .006,
respectively). The subject incidence of SAEs was low and compa-
rable between groups. Conclusion: In chemotherapy-naive sub-
jects with solid tumor, single-day administration of pegﬁlgrastim is
at least as efﬁcacious as repeated daily injections of ﬁlgrastim (10
g/kg) in its ability to successfully mobilize peripheral CD34
cells. A dose-response relationship of CD34 mobilization is ob-
served. Pegﬁlgrastim 12 mg and 18 mg mobilize higher numbers of
CD34 cells than does daily administration of ﬁlgrastim. Pegﬁl-
grastim at 6 mg, 12 mg, and 18 mg is generally safe and well
tolerated in this setting. The trial is ongoing, and updated results
on safety and efﬁcacy will be presented.
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INTERIM ANALYSIS OF A PHASE II STUDY OF RISK-ADAPTED INTRA-
VENOUS MELPHALAN FOLLOWED BY ADJUVANT DEXAMETHASONE
(D) AND THALIDOMIDE (T) FOR NEWLY DIAGNOSED PATIENTS WITH
SYSTEMIC AL AMYLOIDOSIS (AL)
Cohen, A.D.; Zhou, P.; Reich, L.; Fircanis, S.; Drake, L.; Hedvat, C.;
Teruya-Feldstein, J.; Filippa, D.A.; Fleisher, M.; Comenzo, R.L.
Memorial Sloan-Kettering Cancer Center, New York, NY.
High-dose melphalan (M) with autologous stem cell transplant
(ASCT) is effective therapy for AL, but treatment-related mortal-
ity (TRM) remains high, and hematologic complete responses
(CR) occur in a minority of patients. In this study, we investigated
whether a risk-adapted approach to intravenous (IV) M dosing
could decrease TRM, and whether adjuvant D 	 T could improve
hematologic and amyloid-involved organ response rates. Low-risk
patients (1 or 2 major organs involved, no advanced cardiac disease)
receive M 100, 140, or 200 mg/m2 with ASCT based on age,
cardiac involvement, and renal function. High-risk patients (3
organs involved or advanced cardiac disease) receive 2 cycles of M
40 mg/m2 without ASCT. Patients with persistent clonal plasma
cell disease at 3 months receive 9 months of adjuvant DT or D
alone (if history of deep venous thrombosis or neuropathy). Since
September 2002, 39 patients (median age, 58 years; range, 34–73
years; 67% male) have enrolled for a median of 1.5 months (range,
0.5–7 months) from diagnosis. Organ involvement includes 13
(33%) cardiac, 25 (64%) renal (13 with renal only), 13 (33%)
liver/GI tract, and 10 (26%) peripheral nervous system. Only 4
high-risk patients have enrolled; all had symptomatic cardiac in-
volvement and died a median of 4 months (range, 2.5–6 months)
after M. Thirty-four patients in the low-risk group have been
treated, and TRM is 6.4% (2/31), with an additional 3 patients
alive 100 days posttreatment. Four low-risk patients have died of
progressive disease (PD) a median of 11.7 months (range, 7–18
months) after M. At 3 months, 19/30 (63%) evaluable low-risk
patients had hematologic responses (5 CR, 14 PR) and 11 had
stable disease. Twenty patients with persistent clonal disease began
adjuvant therapy with D 	 T. At 12 months, 11/15 (73%) evalu-
able patients had responses (5 CR, 6 PR) and 8 (67%) had objective
improvement in amyloid-related organ function. Preliminary anal-
ysis of serum free light chain data (n  31) shows an association
between a persistently abnormal 
: ratio 3 months after treatment
and an increased risk of death (relative risk 1.54; 95% conﬁdence
interval  1.12–2.12; P  .02). Analyses of the prognostic signif-
icance of serial troponin and BNP levels and plasma cell cyclin D1
expression are ongoing. In conclusion, risk-adapted dosing of IVM
in newly diagnosed AL patients has a low TRM. Adjuvant D 	 T
is feasible, has moderate toxicity, and has to date beneﬁted 20%
(4/20) of patients with persistent clonal plasma cell disease 3
months post-ASCT.
Adjuvant Therapy* (n  25 Eligible)
Thal/Dex (n) Dex (n)
Began therapy (n  5
refused or too ill) 12 8
Completed 9 mos. 4 3
Still on (<9 mos.) 3 2
Reasons for
discontinuation
PD (n  2),
pulmonary embolus
(1), avascular
necrosis hip (1),
RSV pneumonia (1)
PD (n  2),
intolerance (1)
Benefit to
hematologic
response
SD (@3 mos.)3PR
(@12 mos.) (n 
1), PR3CR (n  1)
SD3PR (n  1),
PR3CR (n 
1)
*Dexamethasone (1 to 3 four-day pulses monthly); Thalidomide
(50–200mg nightly)
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IDENTIFICATION AND TISSUE DISTRIBUTION OF ANTIGEN-SPECIFIC
RECIPIENT ANTI-DONOR CD8 T CELLS THAT RESIST HEMATOPIETIC
ENGRAFTMENT FOLLOWING MHC-MATCHED ALLOGENEIC PROGENI-
TOR CELL TRANSPLANTS
Shatry, A.M.; Levy, R.B. University of Miami Medical School, Miami,
FL.
The role of natural killer (NK) cells in resistance to progenitor
cell (PC) engraftment has been extensively studied in experimental
bone marrow transplantation (BMT). Although antigen-speciﬁc T
cells are believed to be the principal effectors resisting engraftment
following clinical hematopietic cell transplants (HCT), less is
known involving the biology and distribution of these cells follow-
ing experimental HCT. The present studies established a model of
resistance using the well-deﬁned dominant, that is H60 MiHA (in
B6 mice primed to BALB.B; B6BALB.B) to precisely identify and
track host T cells following BMT into recipients sensitized against
donor transplant antigens. We utilized an H60/Kb tetramer and
determined the mean (12.2% 	 0.88 of CD8 cells) frequency of
circulating CD8 H60-speciﬁc T cells (5.6%–20.5%) in B6 re-
cipients before BMT. Most ( 90%) CD8H60 cells expressed
the memory phenotype (CD44, Ly6C, CD25/CD69). Inter-
estingly, the frequency of CD8 H60 T cells was higher in the
bone marrow than in the blood and splenic compartments, sug-
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gesting that cells present in this compartment post-BMT may be
composed of both migrants and a resident population. To mediate
resistance to PC engraftment, effector CD8 cells must ﬁrst sur-
vive conditioning and the BMT milieu. B6BALB.B mice irradiated
at 3, 6, and 9 Gy were analyzed 24 hours later for CD8 H60-
speciﬁc T cells in the spleen and BM. Tertramer cells were
clearly identiﬁed in both compartments showing dose-dependent
increases. Importantly, 5 days after HCT with 1  107 H60
congenic (or BALB.B) TCD BM, PC rejection was evident, as
indicated by nondetectable splenic CFU activity in recipients of
these allogeneic, but not syngeneic TCD-BM. Notably, tetramer
cells were again detected in BM and spleen. Interestingly, their
frequency was 3fold higher in the marrow (mean, 6%) than in the
splenic compartment (mean, 1.7%) in sensitized recipients of ei-
ther syngeneic or MiHA allogeneic BM. These increases are con-
sistent with the predicted survival advantage of CD8 memory T
cells due to elevated bcl-2 levels. However, resistance did not occur
in syngeneic recipients due to lack of activation of H60-speciﬁc T
cells. These studies conclusively demonstrate that an antigen-
speciﬁc CD8 T-memory population responsible for resistance sur-
vives allogeneic BMT and is present in bone marrow and spleen
where resistance is presumed to occur. Studies are underway to
functionally and molecularly characterize this MiHA antigen-spe-
ciﬁc population during ongoing resistance post-HCT.
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IMMUNOLOGICAL AUTOLOGOUS STEM CELL GRAFT ENGINEERING US-
ING COMBINATION G-CSF AND ALDESLEUKIN (IL-2) IN PATIENTS
WITH NON-HODGKIN’S LYMPHOMA
Micallef, I.N.; Markovic, S.N.; Geyer, S.; Porrata, L.F.; Ansell, S.M.;
Inwards, D.J.; Gastineau, D.A.; Padley, D.J.; Armstrong, A.S.; Litzow,
M.R. Mayo Clinic College of Medicine, Rochester, MN.
Absolute lymphocyte count (ALC) recovery to  500/l by day
15 post-autologous peripheral blood stem cell transplant (APB-
SCT) is associated with an improved overall and event-free survival
(EFS) for patients with non-Hodgkin’s lymphoma (NHL). The
beneﬁt of the ALC post-APBSCT is likely due to natural killer
(NK) cells, because patients who achieved a normal NK cell count
( 80/l) on day 15 post-APBSCT (day 15 NK) had an improved
EFS compared with those whose day 15 NK was low. Finally, the
day 15 ALC correlates to the infused autograft absolute lympho-
cyte count (A-ALC) and not with total CD34 dose. Thus we
hypothesized that a peripheral blood stem cell mobilization regi-
men would be ideal if it could mobilize CD34 cells, lymphocytes,
and NK cells. A pilot study was undertaken using a sequential
mobilization regimen of granulocyte colony-stimulating factor (G-
CSF) followed by aldesleukin. Patients received G-CSF at 10
g/kg/day, and stem cell collections began on day 5 or later, when
the peripheral blood (PB) CD34 cell count was  10/l. Once
stem cell collection was complete and a minimum of 2 106 CD34
cells/kg were collected, patients received 1 subcutaneous injection
of aldesleukin and underwent 1 further apheresis the next day
collect lymphocytes. The dose levels of aldesleukin were 0, 0.5, 1,
1.5, and 2  106 U/m2. Patients then underwent conditioning for
APBSCT and on day 0 received all of the apheresis product,
including the extra collection of lymphocytes. PB lymphocyte
counts and subset analysis were measured at baseline (before G-
CSF), pre-aldesleukin, 1 day post-aldesleukin, and day 15 post
APBSCT. A total of 43 patients with NHL were entered in the
study. Of these, 26 completed an adequate CD34 collection, re-
ceived aldesleukin, and underwent an extra apheresis. The results
of these 26 patients are presented. The median CD34 collected,
A-ALC, autograft NK collected (A-NK), day 15 ALC, and day 15
NK for each dose level are given. The median times to neutrophil
and platelet engraftment were 13 and 12 days, respectively. We
conclude that aldesleukin up-regulates NK cell numbers. Dose
level 3 resulted in the best NK cell apheresis collection, the highest
PB NK cell count post-aldesleukin, on day 15 NK, and on day 15
ALC. Only at this dose did all patients achieve a normal day 15 NK
cell count. A phase II study is proposed using a sequential regimen
of G-CSF followed by aldesleukin at a dose of 1.5  106/m2 to
conﬁrm these results. Successful lymphocyte and NK cell engraft-
ment post-APBSCT may become as important as neutrophil and
platelet engraftment post-APBSCT.
Dose
Level
IL-2
Dose
#
Patients CD34
Total
A-ALC
Total
A-NK
Day 15
ALC
Day 15
NK
0 0 5 7.36  106/kg 0.57  109/kg 0.09  109/kg 744/l 194/l
1 0.5  106 IU/m2 5 4.37  106/kg 0.47  109/kg 0.09  109/kg 310/l 92/l
2 1  106 IU/m2 5 4.87  106/kg 0.67  109/kg 0.10  109/kg 700/l 120/l
3 1.5  106 IU/m2 5 6.96  106/kg 0.38  109/kg 0.11  109/kg 1380/l 472/l
4 2  106 IU/m2 6 3.73  106/kg 0.43  109/kg 0.10  109/kg 787/l 192/l
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INHIBITORY EFFECTS OF CYTOTOXICITY OF CYTOKINE ACTIVATED
AND EXPANDED HUMAN CD8 T CELLS BY A HUMAN NKG2D ALTER-
NATIVE SPLICE VARIANT
Karimi, M.A.; Cao, T.; Soares, L.; Negrini, R.S. Stanford University,
Stanford, CA.
NKG2D is an activating receptor that is expressed onCD8T cells
and & T cells where it up-regulates activation through T-cell
receptor (TCR) costimulation. NKG2D is triggered by ligands that
are structurally related to major histocompatibility complex (MHC)-1
and expressed by tissues early in ontogeny, stress, and transformation.
The function of NKG2D on natural killer (NK) cells and CD8 T
cells is mediated by 2 distinct pathways of signaling through its
association withDAP10 andDAP12. One functionally distinct human
NKG2D isoform has been identiﬁed. In evaluating human NKG2D
gene expression by reverse-transcription polymerase chain reaction
(RT-PCR) in CD8T cells derived from 7 different donors, we
consistently observed 2 distinct bands differing by 218bp. Cloning and
sequencing of both PCR amplicons revealed a previously described
alternatively spliced NKG2D variant from inclusion of intron 6.
Intron 6 inclusion introduces a stop codon, resulting in a truncated
protein product lacking the entire extracellular domain. To determine
the functional consequences of truncated NKG2D expression, we
isolated and cloned both full-length and truncatedNKG2D into pRJ3
vectors. Human CD8 T cells were tranduced and directed against
human cell line targets in Cr51 cytotoxicity assays. We found that
expression of the full-length NKG2D resulted in a15% increase in
cytotoxicity, whereas expression of the truncated NKG2D resulted in
70% reduction in cytotoxicity. Results were compared to CD8 T
cells transduced with an empty vector. To further elucidate the role of
each NKG2D isoform, we coexpressed full-length and truncated
NKG2D with DAP-10 or DAP-12. Coexpression of full-length
NKG2Dwith either DAP10 orDAP12 resulted in a comparable 25%
cytotoxicity versus NKG2D alone. Coexpression of full-length and
truncated NKG2D also resulted in reduction of up to 65% coexpres-
sion of the truncated NKG2D isoform with DAP10 or DAP12 did
not alter the reduction in cytotoxicity observed with truncated
NKG2D alone.We also performed experiments usingmurine CD8
T cells with human cell line targets. Overexpression of full-length
NKG2D resulted in a  32% increase in cytotoxicity, whereas coex-
pression of full-length NKG2D and DAP10 resulted in a 42% in-
crease in cytotoxicity. Collectively, these results demonstrate that the
NKG2D isform lacking the extracellular domain unexpectedly inhib-
its cytotoxicity in human CD8 T cells. Also of interest is whether
variability in expression of the truncated NKG2D isoform inﬂuences
the cytotoxic potency of activated CD8 T cells expanded from
different donors.
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RABBIT IGG LEVELS IN PATIENTS RECEIVING THYMOGLOBULIN AS
PART OF CONDITIONING BEFORE UNRELATED-DONOR ALLOGENEIC
STEM CELL TRANSPLANTATION
Remberger, M.; Sundberg, B. Karolinska Institutet, Clinical Immunol-
ogy, Karolinska University Hospital, Stockholm, Sweden.
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